Milken Global Conference 2018
AgeneBio Founder Michela Gallagher, PhD, will speak on “Alzheimer’s Disease: Rewriting the Playbook” on Monday, April 30, 2018, at 2:30 pm. The conference will be held at the Beverly Hilton in Beverly Hills, CA.
Posts for category: Events
AgeneBio Founder Michela Gallagher, PhD, will speak on “Alzheimer’s Disease: Rewriting the Playbook” on Monday, April 30, 2018, at 2:30 pm. The conference will be held at the Beverly Hilton in Beverly Hills, CA.
Michela Gallagher will present “Targeting hippocampal overactivity in prodromal Alzheimer’s disease” in the Alzheimer’s Emerging Therapies session, on March 9 at 1:00 pm.
Michela Gallagher will participate in a session on “Emerging Therapeutics” to discuss AgeneBio’s Programs targeting hippocampal hyperactivity in the Mild Cognitive Impairment phase of prodromal Alzheimer’s disease.
Founder and CSO Michela Gallagher, PhD co-chaired a featured symposium, “The Two-Way Street Linking B-Amyloid, Tau and Neural Activity” and presented “Age-Related Network Dysfunction: Contributions of Neural Activity to Risk for Late Onset Alzheimer’s Disease.” Click title link for details.
Vice President of Clinical Development Richard Mohs, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation.
Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation. During the conference, Dr. Rosenzweig-Lipson was interviewed by NJTV News.
CEO Jerry McLaughlin will present at the Neuroscience BioPartnering & Investment Forum on Tuesday, February 23, at 3:35 pm Eastern Time. The BIO CEO & Investor Conference is being held at The New York Academy of Sciences.
CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at 10:15 am Eastern Time. The BIO CEO & Investor Conference is being held February 8 and 9 at the Waldorf Astoria New York.
CEO Jerry McLaughlin will participate on a panel entitled, “Access to Medicine: Charities, Academics & Industry Collaboration for New Treatments,” on Thursday, December 3, at 3:45 pm Pacific Time.
CEO Jerry McLaughlin will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” on November 19 in Boston.